M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
M V Chandrakanth, Academic Head and Medical Oncologist at Narayana Health, shared a post on LinkedIn:
“Aspirin in CRC – Old Drug, New Precision Oncology?
ALASCCA | 4-part quick revision
Part 1 – Why Aspirin?
The biology: PI3K–COX/PGE2 signaling and platelet-mediated metastatic escape as proposed mechanisms.
Part 2 – Who Got Aspirin?
Resected localized CRC and PI3K-pathway alteration – aspirin 160 mg/day vs placebo × 3 years.
Part 3 – Did it Work?
Primary Group A: 3-year recurrence 14.1% – 7.7% | HR 0.49.
Benefit also seen in the broader PI3K-altered Group B; absolute benefit was greater in higher-risk disease.
Part 4 – What Does It Men?
A compelling example of biomarker-directed drug repurposing – but OS benefit is not yet proven, and subgroup signals require caution.
Take-home:
Not aspirin for every CRC – aspirin for the right biology.”

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 09:41Girishkumar Modi: Navigating the 2026 Jehovah’s Witness Transfusion Policy Shift in Clinical Practice
-
Nov 15, 2026, 04:31Aakriti Gupta: Anticoagulation for Leaflet Thickening After TAVR
-
Nov 14, 2026, 23:57Jamie S. Y. Ho: Exploring the Mechanisms of Arterial Thrombosis and the Evolution of Antithrombotic Therapy
-
Nov 14, 2026, 23:53Jacopo Imberti: The Past, Present and Future of Arterial Thrombosis Research
-
Nov 14, 2026, 23:48Shrouk Ramadan: Joining the Editorial Review Board of Clinical and Applied Thrombosis and Hemostasis
-
Nov 14, 2026, 23:46Habib Bennaceur: Moving Towards Fewer Limitations for People Living With Haemophilia
-
Nov 14, 2026, 23:44Paul Healy: EU Approves Frehemgo for Haemophilia A
-
Nov 14, 2026, 23:43Mehak Trehan: ASH 2026 Benign Hematology – Ten Abstracts Through an Indian Lens
-
Nov 14, 2026, 23:33Felipe Magalhaes Furtado: Artificial Intelligence Advances PNH Clone Detection Through Machine Learning